The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Gov. Josh Shapiro is warning that cuts to Medicaid health care that Congress is considering would mean billions of dollars in lost federal aid to Pennsylvania, hundreds of thousands of people losing a ...

The analysis of 11 weight-loss drug studies by the University of Oxford found that patients typically lost 8kg (18lb) after ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Weight loss drugs have been pitted against each other in a first of its kind head-to-head trial. Mounjaro and Wegovy were put ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

President Donald Trump told Fox News host Sean Hannity that the pal who starred in the "fat shot" story was "very worried" ...